This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liede, A. Articles by Narod, S. A. Search for Related Content PubMed PubMed Citation Articles by Liede, A. Articles by Narod, S. A.

Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature

From the Women's Cancer Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; and Centre for Research in Women's Health, Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario, Canada

Address reprint requests to Alexander Liede, MD, Women's Cancer Research Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Suite 290W, Los Angeles, CA 90048; e-mail: liede{at}email.com.

Major risks conferred by BRCA1 and BRCA2 in women are for cancers of the breast, ovary, fallopian tube, and peritoneum. Male carriers of mutations in BRCA1 or BRCA2 are also susceptible to cancer; however, their risks remain poorly understood and their optimal clinical management has not yet been defined. This article reviews studies that estimate risk associated with mutations in BRCA1 or BRCA2, with a focus on the cancer sites most relevant to men. Male BRCA1 mutation carriers are at increased risk of cancers of the prostate and breast. Evidence supporting increased susceptibility to colon cancer is limited. In contrast to women, who have a greater lifetime risk of cancer with mutations of the BRCA1 gene, BRCA2 is the more important gene for men. The spectrum of cancers is wide for BRCA2 and some studies report that the overall cancer risk for male BRCA2 carriers exceeds the risk for female carriers. In particular, the relative risk to male BRCA2 mutation carriers is high before age 65 years, largely attributable to breast, prostate, and pancreatic cancers. BRCA2 mutation carriers are also at risk of stomach cancer and melanoma (of the skin and eye). Additional research into risks to male BRCA1 or BRCA2 mutation carriers is necessary, specifically to determine the magnitude of excess cancer risk among BRCA2 carriers and to increase our understanding of the basis for the observed site-specificity in cancer development.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				B. N. Peshkin, T. A. DeMarco, J. E. Garber, H. B. Valdimarsdottir, A. F. Patenaude, K. A. Schneider, M. D. Schwartz, and K. P. Tercyak Brief Assessment of Parents' Attitudes Toward Testing Minor Children for Hereditary Breast/Ovarian Cancer Genes: Development and Validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS) J. Pediatr. Psychol., April 1, 2008; (2008) jsn033v1. [Abstract] [Full Text] [PDF]

				F. H. Vaz, P. M. Machado, R. D. Brandao, C. T. Laranjeira, J. S. Eugenio, A. H. Fernandes, and S. P. Andre Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients J. Histochem. Cytochem., November 1, 2007; 55(11): 1105 - 1113. [Abstract] [Full Text] [PDF]

				P. M. Machado, R. D. Brandao, B. M. Cavaco, J. Eugenio, S. Bento, M. Nave, P. Rodrigues, A. Fernandes, and F. Vaz Screening for a BRCA2 Rearrangement in High-Risk Breast/Ovarian Cancer Families: Evidence for a Founder Effect and Analysis of the Associated Phenotypes J. Clin. Oncol., May 20, 2007; 25(15): 2027 - 2034. [Abstract] [Full Text] [PDF]

				R. D. Kennedy and A. D. D'Andrea DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes J. Clin. Oncol., August 10, 2006; 24(23): 3799 - 3808. [Abstract] [Full Text] [PDF]

				L. Moro, A. A. Arbini, E. Marra, and M. Greco Up-regulation of Skp2 after Prostate Cancer Cell Adhesion to Basement Membranes Results in BRCA2 Degradation and Cell Proliferation J. Biol. Chem., August 4, 2006; 281(31): 22100 - 22107. [Abstract] [Full Text] [PDF]

				A. Borkhardt, U. Fuchs, T. Tuschl, W. J. Chng, G. A. Calin, A. Cimmino, and C. M. Croce MicroRNA in chronic lymphocytic leukemia. N. Engl. J. Med., February 2, 2006; 354(5): 524 - 525. [Full Text] [PDF]

				A. F. Patenaude, M. Dorval, L. S. DiGianni, K. A. Schneider, A. Chittenden, and J. E. Garber Sharing BRCA1/2 Test Results With First-Degree Relatives: Factors Predicting Who Women Tell J. Clin. Oncol., February 1, 2006; 24(4): 700 - 706. [Abstract] [Full Text] [PDF]

				R. D. Kennedy and A. D. D'Andrea The Fanconi Anemia/BRCA pathway: new faces in the crowd Genes & Dev., December 15, 2005; 19(24): 2925 - 2940. [Abstract] [Full Text] [PDF]

				H. D. Nelson, L. H. Huffman, R. Fu, and E. L. Harris Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force Ann Intern Med, September 6, 2005; 143(5): 362 - 379. [Abstract] [Full Text] [PDF]

				E M Rosen, S Fan, and C Isaacs BRCA1 in hormonal carcinogenesis: basic and clinical research Endocr. Relat. Cancer, September 1, 2005; 12(3): 533 - 548. [Abstract] [Full Text] [PDF]

				L. Moro, A. A. Arbini, E. Marra, and M. Greco Down-regulation of BRCA2 Expression by Collagen Type I Promotes Prostate Cancer Cell Proliferation J. Biol. Chem., June 10, 2005; 280(23): 22482 - 22491. [Abstract] [Full Text] [PDF]

				L. C. Friedman and R. M. Kramer Reproductive Issues for Women With BRCA Mutations J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 83 - 86. [Abstract] [Full Text] [PDF]

				R. Fan, T. S. Kumaravel, F. Jalali, P. Marrano, J. A. Squire, and R. G. Bristow Defective DNA Strand Break Repair after DNA Damage in Prostate Cancer Cells: Implications for Genetic Instability and Prostate Cancer Progression Cancer Res., December 1, 2004; 64(23): 8526 - 8533. [Abstract] [Full Text] [PDF]

				I. Tournier, B. B.-d. Paillerets, H. Sobol, D. Stoppa-Lyonnet, R. Lidereau, M. Barrois, S. Mazoyer, F. Coulet, A. Hardouin, A. Chompret, et al. Significant Contribution of Germline BRCA2 Rearrangements in Male Breast Cancer Families Cancer Res., November 15, 2004; 64(22): 8143 - 8147. [Abstract] [Full Text] [PDF]

				K. A. Zuhlke, J. J. Madeoy, J. Beebe-Dimmer, K. A. White, A. Griffin, E. M. Lange, S. B. Gruber, E. A. Ostrander, and K. A. Cooney Truncating BRCA1 Mutations Are Uncommon in a Cohort of Hereditary Prostate Cancer Families with Evidence of Linkage to 17q Markers Clin. Cancer Res., September 15, 2004; 10(18): 5975 - 5980. [Abstract] [Full Text] [PDF]